Skip to content
ATLAS PREP HQ
Fat Loss

Cagrilintide

Long-acting acylated amylin analogue

Long-acting amylin-analog research focused on appetite regulation, satiety, and body-weight reduction.

Strong Human Evidence

Route

Subcutaneous.

Common format

5 mg vial

Research focus

obesity

Evidence level

Strong Human Evidence

Typical cycle

12–16+ weeks

Fat Loss research motifFat Loss

Cagrilintide in 30 seconds

Atlas Fast Read

What it is

Long-acting acylated amylin analogue

Why people care

Long-acting amylin-analog research focused on appetite regulation, satiety, and body-weight reduction.

Human evidence

Strong Human Evidence — Substantial randomized or late-phase human evidence with clinically meaningful outcomes, and/or well-established clinical use relevant to the stated claim.

Biggest misconception

Evidence is strong for specific studied endpoints, but important gaps can remain around long-term comparative safety, optimal sequencing, use outside approved/studied populations, and broader performance or longevity claims.

Bottom line

Cagrilintide has moved beyond peptide-theory territory into serious obesity-drug evidence.

Overview

What is Cagrilintide?

Cagrilintide is long-acting acylated amylin analogue. Long-acting amylin-analog research focused on appetite regulation, satiety, and body-weight reduction.

Developed by Novo Nordisk as a long-acting amylin analogue for obesity treatment. Dose-ranging human trials in the 2020s showed clinically meaningful weight loss and led to combination development with semaglutide.

Mechanism

How it works

Activates amylin receptors in the CNS and gastrointestinal system, increasing satiety, slowing gastric emptying, and reducing food intake. Acylation extends exposure enough for once-weekly dosing.

Research areas

obesitysatietyappetite regulationmetabolic disease

Evidence

What does the evidence actually say?

Strong Human Evidence

Substantial randomized or late-phase human evidence with clinically meaningful outcomes, and/or well-established clinical use relevant to the stated claim.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Cagrilintide has substantial randomized human trial evidence showing dose-dependent weight loss and appetite effects in people with overweight or obesity. Its evidence is strong for obesity-related endpoints, although regulatory status and final approved labeling may still differ from trial protocols.

Preclinical evidence

Animal models supported prolonged amylin-receptor agonism, reduced food intake, and body-weight reduction and informed human dose development. Human trials are now more informative than the preclinical base.

Knowledge gaps

Evidence is strong for specific studied endpoints, but important gaps can remain around long-term comparative safety, optimal sequencing, use outside approved/studied populations, and broader performance or longevity claims.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Human trials have studied once-weekly dose escalation up to 4.5 mg. Community reference: 0.6 → 1.2 → 2.4 → 4.5 mg weekly.

Frequency

Once weekly.

Timing

Same day each week; time of day is not usually critical.

Route

Subcutaneous.

Cycle length

12–16+ weeks

Reconstitution

Community research-vial reference: 1 mL bacteriostatic water per 5 mg vial = 5 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C, protected from light, use within about 30 days.

Monitoring

Weight, waist, blood pressure, hydration/nutrition, fasting glucose/HbA1c, renal/hepatic function as indicated, and GI adverse effects. Monitor for symptoms suggesting pancreatitis or gallbladder disease.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Most common effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite and reflux. Clinically important risks can include dehydration/acute kidney injury, gallbladder disease and pancreatitis; rapid weight loss can contribute to lean-mass loss.

Contraindications

Cagrilintide remains investigational and has no final approved contraindication profile. Pregnancy, severe GI motility disorders, significant pancreatitis/gallbladder risk and hypersensitivity warrant exclusion or specialist review in research settings.

Interactions

Slower gastric emptying can change absorption/timing of oral medicines. When combined with insulin or insulin secretagogues, hypoglycemia risk can rise; dose adjustment belongs under medical supervision. Do not combine overlapping incretin therapies unless specifically studied/prescribed.

Stacks

Common stacks

Cagrilintide + Semaglutide

This is a genuine clinical-development combination (CagriSema) targeting amylin and GLP-1 pathways.

Strong human trial evidence for weight-loss/metabolic endpoints; final regulatory labeling matters.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Cagrilintide has moved beyond peptide-theory territory into serious obesity-drug evidence. The human weight-loss signal is strong; the remaining questions are about long-term outcomes, regulatory labeling, comparative positioning, tolerability, and maintenance.

More in Fat Loss

Fat Loss

5-Amino-1MQ

Selective NNMT-inhibitor research focused on cellular energy balance and metabolic function.

Read guide

Fat Loss

AOD-9604

Modified growth-hormone fragment studied for lipolysis and fat-metabolism effects without targeting IGF-1.

Read guide

Fat Loss

Cagrilintide + Semaglutide

Dual amylin and GLP-1 pathway research aimed at appetite control and significant weight reduction.

Read guide